Literature DB >> 9096095

Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose.

B Woesler1, T Kuwert, C Morgenroth, P Matheja, S Palkovic, M Schäfers, B Vollet, K Schäfers, H Lerch, W Brandau, S Samnick, H Wassmann, O Schober.   

Abstract

Use of iodine-123-alpha-methyl tyrosine (123I-IMT) allows investigation of the amino acid transport rate in gliomas. It was the aim of this study to compare the value of measurement of glucose metabolism with that of measurement of 123I-IMT uptake for the non-invasive grading of brain tumours. The study population comprised 23 patients with histopathologically proven primary brain tumours; 14 had high-grade gliomas, and nine low-grade brain neoplasms. Glucose metabolism was studied using an ECAT EXACT 47 positron emission tomography (PET) camera and fluorine-18 fluorodeoxyglucose (18F-FDG); 123I-IMT uptake was measured with the triple-headed single-photon emission tomography (SPET) camera, MULTISPECT 3. 18F-FDG and 123I-IMT uptake was quantified as ratios between the uptake by the tumour and contralateral regions of reference. Glucose metabolism and amino acid uptake of the brain tumours correlated significantly (r=0.71, P <0.001). Assuming discrimination thresholds between high-grade and low-grade tumours of 0.8 for 18F-FDG uptake and 1.8 for 123I-IMT uptake, the accuracy values of 18F-FDG PET and 123I-IMT SPET for differentiating between high-grade and low-grade tumours were 21/23 (91%) and 19/23 (83%), respectively. The difference in diagnostic performance was not significant on receiver operating characteristic analysis (P >0.4). It is concluded that there is no major difference between the PET investigation of glucose metabolism and the less expensive SPET measurement of amino acid uptake in terms of their accuracy in evaluating the malignancy grade of primary brain tumours. This encourages the performance of further studies to analyse the potential impact of 123I-IMT SPET on the therapeutic management of patients with brain tumours.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096095     DOI: 10.1007/bf00881816

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

Review 1.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

2.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

3.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.

Authors:  M Weckesser; K J Langen; C H Rickert; S Kloska; R Straeter; K Hamacher; G Kurlemann; H Wassmann; H H Coenen; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-14       Impact factor: 9.236

4.  Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

5.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

6.  Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas.

Authors:  Dirk Hellwig; Bernd F M Romeike; Ralf Ketter; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

7.  Differentiating solitary brain metastases from glioblastoma by radiomics features derived from MRI and 18F-FDG-PET and the combined application of multiple models.

Authors:  Xu Cao; Duo Tan; Zhi Liu; Meng Liao; Yubo Kan; Rui Yao; Liqiang Zhang; Lisha Nie; Ruikun Liao; Shanxiong Chen; Mingguo Xie
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

8.  [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.

Authors:  Christian Pötzi; Alexander Becherer; Christine Marosi; Georgios Karanikas; Monika Szabo; Robert Dudczak; Kurt Kletter; Susanne Asenbaum
Journal:  J Neurooncol       Date:  2007-05-11       Impact factor: 4.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.